Pet Drug Reports

Drugs by active ingredient

Drug · single active ingredient

Cisapride: adverse event reports

All products with this active ingredient · not in an FDA-approved animal drug

152reports naming this ingredient, 2001–20260% of all reports · about 6 a year
28reports, 12 months to March 202645 in the 12 months before
53%classed serious, as reportedof 149 reports stating it
14.5%record death or euthanasia, as reported22 reports
67.8%of reports concern cats0.1% of all cat reports

Between September 2001 and March 2026 FDA received 152 adverse event reports listing a drug with cisapride as the recorded active ingredient. It is not the active ingredient of an FDA-approved animal drug; it reaches animals through human-label or compounded products.

openFDA masks the brand and manufacturer in every report, so these figures describe the ingredient across all products and cannot be attributed to a brand.

In the 12 months to March 2026, 28 reports named it, down 38% from 45 in the 12 months before. Recent months are provisional: fDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Over its whole reporting history that is about 6 reports a year and 0% of all 1,357,245 reports (0.1% of all cat reports). How many animals received it is not published, so a count says nothing about how often a problem occurs per dose.

Reporters most often listed lethargy (16.4%), vomiting (16.4%) and decreased appetite (13.2%). A report can list several signs, so shares add to more than 100%; 492 different terms appear across these reports.

67.8% of reports concern cats. Not every report describes illness: 11.8% were filed wholly or partly as lack of expected effectiveness. Of reports that state seriousness, 53% were classed as serious, and 14.5% of all reports record a death or euthanasia as an outcome, as reported. FDA has not necessarily determined whether any drug played a part.

Monthly reports by species, five years

Dog32 · peak 3
Jan 2022: 2Feb 2022: 1Mar 2023: 2May 2023: 1Aug 2023: 1Oct 2023: 1Feb 2024: 1Mar 2024: 1Apr 2024: 3Aug 2024: 1Sep 2024: 1Oct 2024: 1Nov 2024: 2Dec 2024: 1Jan 2025: 1Feb 2025: 1Apr 2025: 1Jun 2025: 1Jul 2025: 1Aug 2025: 1Oct 2025: 1Nov 2025: 1Jan 2026: 1Feb 2026: 2Mar 2026: 22022202320242025
Cat74 · peak 5
Oct 2021: 1Dec 2021: 2May 2022: 1Jun 2022: 1Nov 2022: 2Feb 2023: 1Mar 2023: 3May 2023: 1Jun 2023: 1Jul 2023: 1Aug 2023: 4Nov 2023: 1Dec 2023: 2Jan 2024: 1Feb 2024: 1Mar 2024: 1Apr 2024: 3May 2024: 1Jun 2024: 4Jul 2024: 2Aug 2024: 5Sep 2024: 4Oct 2024: 2Dec 2024: 4Jan 2025: 3Feb 2025: 3Mar 2025: 3Apr 2025: 1May 2025: 3Jun 2025: 2Jul 2025: 1Sep 2025: 2Nov 2025: 1Dec 2025: 1Jan 2026: 3Mar 2026: 22022202320242025
Horse0 · peak 1
2022202320242025
Other1 · peak 1
Oct 2025: 12022202320242025

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

020392001: 120012004: 12011: 120112012: 22013: 420132014: 32015: 220152016: 52017: 420172018: 82019: 520192020: 72021: 520212022: 72023: 1920232024: 392025: 2920252026: 10

2026 covers reports received through March 2026 only.

Signs listed in reports

share of cisapride reports listing the termall cat reports

  1. Lethargy[unusually tired or inactive]16.4%25
  2. Vomiting16.4%25
  3. Death by euthanasia[the animal was euthanized]12.5%19
  4. Lack of efficacy - NOS[the product did not have the expected effect]10.5%16
  5. Anorexia[not eating]9.2%14
  6. Diarrhoea[diarrhea]9.2%14
  7. Other abnormal test result NOS[abnormal laboratory result, type not specified]9.2%14
  8. Ataxia[unsteady, uncoordinated movement]6.6%10
  9. Elevated blood urea nitrogen (BUN)[a kidney value above the normal range]6.6%10
  10. Hypokalaemia[low blood potassium]5.9%9
  11. Elevated creatinine[a kidney value above the normal range]5.3%8
  12. Hyperglycaemia[high blood sugar]5.3%8
  13. Hypoalbuminaemia[low blood albumin]5.3%8
  14. Ketosis[ketones building up in the body]5.3%8
  15. Neutrophilia[high neutrophil count]5.3%8
  16. Behavioural disorder NOS[behaviour change, type not specified]4.6%7
  17. Intentional misuse[use that was knowingly different from the label]4.6%7
  18. Intestinal disorder NOS[NOS: not otherwise specified]4.6%7
  19. Elevated symmetrical dimethylarginine (SDMA)[a kidney value above the normal range]3.9%6

Top 30 of 492 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Outcome recorded in the report

Recovered/Normal13.8%21
Recovered with Sequela0.7%1
Ongoing45.4%69
Died2%3
Euthanized12.5%19
Outcome Unknown24.3%37

What kind of report it was

Safety issue86.2%131
Lack of expected effectiveness3.3%5
Both safety and lack of expected effectiveness8.6%13
Manufacturing or product defect1.3%2
Other0.7%1

Coloured bar: reports naming cisapride. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Species

Cat67.8%103
Dog31.6%48
Rabbit0.7%1

Single-breed animals

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Age of the animal

Under 1 year2%3
1 to 3 years5.3%8
4 to 7 years9.9%15
8 to 11 years28.3%43
12 years and over53.3%81
Age not given1.3%2

Weight of the animal

Under 5 kg (11 lb)35.5%54
5 to 9.9 kg (11–22 lb)40.1%61
10 to 24.9 kg (22–55 lb)11.8%18
25 to 44.9 kg (55–99 lb)9.9%15
45 kg and over (99 lb+)0.7%1
Weight not given2%3

Route of administration stated in reports: oral (73).

In context

MeasureCisaprideAll cat reportsAll reports
Reports152148,0801,357,245
Share of that pool's reports naming this drug—0.1%0%
Classed serious, of reports stating it53%35.6%38.6%
Death or euthanasia recorded, per 1,000 reports144.79563.8
Filed as lack of expected effectiveness (wholly or partly)11.8%—23%
Top term, share of reportsLethargy 16.4%9.7%—

This set accounts for 100% of all reports naming cisapride, so no separate ingredient column is shown. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

FDA-approved products (Green Book)

Reference information, not report statistics. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand. The list below is the FDA Green Book as of 1 Oct 2026; nothing on this page says which of these products, if any, a report concerned.

The Green Book lists no approved animal drug with these ingredients. Reports reach FDA for human-label and compounded drugs that veterinarians prescribe.

Species are the major species the Green Book search lists for the application ("—" where it lists another species or none). Approval dates are not part of the Green Book listing files and are not shown. Pioneer applications (NADA) come first, then generics (ANADA).

Questions about cisapride reports

How many adverse event reports has FDA received for cisapride?

152 reports record a drug with cisapride as its active ingredient in the openFDA release of 28 Sep 2026, covering reports received through March 2026. 28 of them arrived in the latest 12 months.

Which brand do these reports concern?

That cannot be known from the public data. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

What signs are reported most often?

lethargy (16.4%), vomiting (16.4%), decreased appetite (13.2%), death by euthanasia (12.5%) and weight loss (12.5%). These are the coded terms listed in reports; several can appear in one report, and a term's presence is not a finding that the drug was responsible.

Which species and breeds appear in these reports?

cat (67.8%), dog (31.6%) and rabbit (0.7%). Among single-breed animals the most frequent labels are Domestic Shorthair, Domestic Longhair, Domestic Mediumhair and Labrador Retriever; popular breeds appear often in any drug's reports because there are more of them.

Are reports rising?

28 reports in the 12 months to March 2026, down 38% from 45 in the 12 months before. FDA posts reports quarterly with a delay of three to six months, so the newest months are incomplete and usually grow in later releases. Counts also move with sales, publicity and time on the market.

Do these reports show that cisapride harms pets?

Report counts cannot show that. FDA states that "there is no certainty that the reported drug or device caused the adverse event" and that the event "may have been related to an underlying disease, other drugs used at the same time or other non-drug related sources." FDA also notes that commonly used products may have more reports simply because more animals receive them.

Are these the side effects of cisapride?

They are signs listed in reports, not an established list of side effects. The adverse reactions observed in studies are printed on each product's FDA-approved label, which a veterinarian can go through with you. This page is a record of what was reported to FDA.

How do I report a problem with an animal drug?

FDA asks owners and veterinarians to call the drug company first (the number is on the label); companies must pass reports to FDA. Reports can also go directly to FDA on Form FDA 1932a. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.